Interní Med. 2010; 12(9): 434-438

Insulins and cancer

MUDr.Daniel Housa, Ph.D.1, MUDr.Jitka Housová, Ph.D.2, prof.MUDr.©těpán Svačina, DrSc., MBA2, prof.MUDr.Martin Haluzík, DrSc.2
1 Ústav patologie 3. LF UK a FNKV Praha, 23. interní klinika 1. LF UK a VFN Praha

The article deals with the relation of insulin to development and progression of cancer and its molecular-biology basis with emphasis

on IGF system. Concurrently the article mentions the present hot topic of the relation of insulin glargine to cancer.

Keywords: insulin, cancer, glargine

Published: October 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Housa D, Housová J, Svačina MBA ©, Haluzík M. Insulins and cancer. Interní Med. 2010;12(9):434-438.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Insulin glargine (Lantus) and cancer risk. Med Lett Drugs Ther, 2009; 51(1319): 67-68. Go to PubMed...
    2. Ciardullo AV, Bacchelli M, Daghio MM, et al. Effectiveness and safety of insulin glargine in the therapy of complicated or secondary diabetes: clinical audit. Acta Diabetol, 2006; 43(2): 57-60. Go to original source... Go to PubMed...
    3. Colhoun HM. Use of insulin glargine and cancer incidence in Scotland: a study from the Scottish Diabetes Research Network Epidemiology Group. Diabetologia 2009; 52(9): 1755-1765. Go to original source... Go to PubMed...
    4. Currie CJ, Poole CD, Gale EA. The influence of glucoselowering therapies on cancer risk in type 2 diabetes. Diabetologia 2009; 52(9): 1766-1777. Go to original source... Go to PubMed...
    5. Gale EA. Insulin glargine and cancer: another side to the story? Lancet 2009; 374(9689): 521. Go to original source... Go to PubMed...
    6. Garg SK, Hirsch IB, Skyler JS. Insulin glargine and canceran unsubstantiated allegation. Diabetes Technol Ther, 2009; 11(8): 473-476. Go to original source... Go to PubMed...
    7. Giovannucci E, Harlan DM, Archer MC, et al. Diabetes and cancer: a consensus report. Diabetes Care 2010; 33: 1674- 1685. Go to original source... Go to PubMed...
    8. Hemkens LG, Grouven U, Bender R, et al. Risk of malignancies in patients with diabetes treated with human insulin or insulin analogues: a cohort study. Diabetologia 2009; 52(9): 1732-1744. Go to original source... Go to PubMed...
    9. Home PD, Lagarenne P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. Diabetologia. 2009; Sep 15. Go to original source... Go to PubMed...
    10. Housa D, Housova J, Vernerova Z, Haluzik M. Adipocytokines and cancer. Physiol Res. 2006; 55: 233-244. Go to original source...
    11. Idris I. Observational registry database studies link insulin glargine with cancer risk. Diabetes Obes Metab, 2009; 11(9): 910-912. Go to original source... Go to PubMed...
    12. Jonasson JM, Ljung R, Talback M, et al. Insulin glargine use and short-term incidence of malignancies-a population-based follow-up study in Sweden. Diabetologia 2009; 52(9): 1745-1754. Go to original source... Go to PubMed...
    13. Lee Ming C, Chia-Hsuin C, Wen-Yi S, Mei-Shu L. in 70th Scientific Sessions (2010) American Diabetes Association.
    14. Le Roith D. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes. Diabetes Metab Res Rev, 2007; 23(8): 593-599. Go to original source... Go to PubMed...
    15. Li D, Yeung SC, Hassan MM, et al. Antidiabetic therapies affect risk of pancreatic cancer. Gastroenterology 2009; 137(2): 482-488. Go to original source... Go to PubMed...
    16. Liefvendahl E, Arnqvist HJ. Mitogenic effect of the insulin analogue glargine in malignant cells in comparison with insulin and IGF-I. Horm Metab Res, 2008; 40(6): 369-374. Go to original source... Go to PubMed...
    17. Mannucci E, Monami M, Balzi D, et al. Doses of Insulin and Its Analogues and Cancer Occurrence in Insulin-Treated Type 2 Diabetic Patients. Diabetes Care, doi: dc10-0476 [pii].
    18. Mayer D, Shukla A, Enzmann H. Proliferative effects of insulin analogues on mammary epithelial cells. Arch Physiol Biochem 2008; 114(1): 38-44. Go to original source... Go to PubMed...
    19. Rosenstock J, Fonseca V, McGill JB, et al. Similar risk of malignancy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: findings from a 5 year randomised, open-label study. Diabetologia 2009; 52(9): 1971-1973. Go to original source... Go to PubMed...
    20. Shukla A. (2008) Insulin analogues: analysis of proliferative potency and characterization of receptors and signalling pathways activated in human mammary epithelial cells. Disertační práce. Combined Faculties for the Natural Sciences and for Mathematics, Doctor of Natural Sciences, Ruperto-Carola University of Heidelberg, Heidelberg.
    21. Staiger K, Hennige AM, Staiger H, et al. Comparison of the mitogenic potency of regular human insulin and its analogue glargine in normal and transformed human breast epithelial cells. Horm Metab Res, 2007; 39(1): 65-67. Go to original source... Go to PubMed...
    22. Staiger K, Staiger H, Schweitzer MA, et al. Insulin and its analogue glargine do not affect viability and proliferation of human coronary artery endothelial and smooth muscle cells. Diabetologia 2005; 48(9): 1898-1905. Go to original source... Go to PubMed...
    23. Tuffs A. German agency suspects that insulin analogue glargine increases risk of cancer. BMJ 2009; 339: b2774. Go to original source... Go to PubMed...
    24. Weinstein D, Simon M, Yehezkel E, et al. Insulin analogues display IGF-I-like mitogenic and anti-apoptotic activities in cultured cancer cells. Diabetes Metab Res Rev, 2009; 25(1): 41-49. Go to original source... Go to PubMed...
    25. Zelobowska K, Gumprecht J, Grzeszczak W. Mitogenic potency of insulin glargine. Endokrynol Pol, 2009; 60(1): 34-39. Go to PubMed...
    26. http://www.diabetologia-journal.org/cancer.html

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.